Clinical Updates
Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin
This review analyzes the prognostic value of the 2022 Heart Failure staging in patients with diabetes and kidney disease, highlighting the high risk of asymptomatic ‘Pre-HF’ and the consistent therapeutic benefits of sotaglifloz
